Angioarchitecture of Hereditary Arteriovenous Malformations

Abstract

This article describes three hereditary conditions known to be associated with arteriovenous malformation (AVM), along with their clinical and imaging features and angiographic angioarchitecture. Hereditary hemorrhagic telangiectasia, capillary malformation–AVM (CM–AVM), and PTEN tumor hamartoma syndrome are conditions with autosomal dominant inheritance, caused by mutations in different molecular pathways, which frequently present with symptomatic AVMs. Imaging biomarkers, including sites of predilection, angioarchitecture, and tissue overgrowth patterns, are helpful in identifying these patients and selecting appropriate treatment.

Keywords

arteriovenous malformation - capillary malformation–arteriovenous malformation - hereditary hemorrhagic telangiectasia - PTEN tumor hamartoma syndrome - genetic mutations

• References

• 1 Park KB, Do YS, Kim DI. , et al. Predictive factors for response of peripheral arteriovenous malformations to embolization therapy: analysis of clinical data and imaging findings. J Vasc Interv Radiol 2012; 23 (11) 1478-1486
• 2 Houdart E, Gobin YP, Casasco A, Aymard A, Herbreteau D, Merland JJ. A proposed angiographic classification of intracranial arteriovenous fistulae and malformations. Neuroradiology 1993; 35 (05) 381-385
• 3 Razek AA, Gaballa G, Megahed AS, Elmogy E. Time resolved imaging of contrast kinetics (TRICKS) MR angiography of arteriovenous malformations of head and neck. Eur J Radiol 2013; 82 (11) 1885-1891
• 4 Cho SK, Do YS, Kim DI. , et al. Peripheral arteriovenous malformations with a dominant outflow vein: results of ethanol embolization. Korean J Radiol 2008; 9 (03) 258-267
• 5 Sabbà C, Pasculli G, Lenato GM. , et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5 (06) 1149-1157
• 6 Giordano P, Lenato GM, Suppressa P. , et al. Hereditary hemorrhagic telangiectasia: arteriovenous malformations in children. J Pediatr 2013; 163 (01) 179-186.e1–e3
• 7 Mei-Zahav M, Letarte M, Faughnan ME, Abdalla SA, Cymerman U, MacLusky IB. Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience. Arch Pediatr Adolesc Med 2006; 160 (06) 596-601
• 8 White Jr RI, Mitchell SE, Barth KH. , et al. Angioarchitecture of pulmonary arteriovenous malformations: an important consideration before embolotherapy. AJR Am J Roentgenol 1983; 140 (04) 681-686
• 9 Tau N, Atar E, Mei-Zahav M. , et al. Amplatzer vascular plugs versus coils for embolization of pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Cardiovasc Intervent Radiol 2016; 39 (08) 1110-1114
• 10 Kajiwara K, Urashima M, Yamagami T. , et al. Venous sac embolization of pulmonary arteriovenous malformation: safety and effectiveness at mid-term follow-up. Acta Radiol 2014; 55 (09) 1093-1098
• 11 Brinjikji W, Iyer VN, Wood CP, Lanzino G. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis. J Neurosurg 2016; 1-9 . doi:10.3171/2016.7.JNS16847. [Epub ahead of print]
• 12 Krings T, Kim H, Power S. , et al; Brain Vascular Malformation Consortium HHT Investigator Group. Neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol 2015; 36 (05) 863-870
• 13 Yang W, Liu A, Hung AL. , et al. Lower risk of intracranial arteriovenous malformation hemorrhage in patients with hereditary hemorrhagic telangiectasia. Neurosurgery 2016; 78 (05) 684-693
• 14 Willemse RB, Mager JJ, Westermann CJ, Overtoom TT, Mauser H, Wolbers JG. Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic telangiectasia. J Neurosurg 2000; 92 (05) 779-784
• 15 Brinjikji W, Nasr DM, Cloft HJ, Iyer VN, Lanzino G. Spinal arteriovenous fistulae in patients with hereditary hemorrhagic telangiectasia: a case report and systematic review of the literature. Interv Neuroradiol 2016; 22 (03) 354-361
• 16 Krings T, Ozanne A, Chng SM, Alvarez H, Rodesch G, Lasjaunias PL. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005; 47 (10) 711-720
• 17 Mahadevan J, Ozanne A, Yoshida Y. , et al. Hereditary haemorrhagic telangiectasia cerebrospinal localization in adults and children. Review of 39 cases. Interv Neuroradiol 2004; 10 (01) 27-35
• 18 Buscarini E, Buscarini L, Civardi G, Arruzzoli S, Bossalini G, Piantanida M. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol 1994; 163 (05) 1105-1110
• 19 Alam MA, Sami S, Babu S. Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide. BMJ Case Rep 2011; 2011: 201
• 20 Dupuis-Girod S, Ginon I, Saurin JC. , et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307 (09) 948-955
• 21 Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol (Providence) 2014; 5 (02) 91-95
• 22 Macmurdo CF, Wooderchak-Donahue W, Bayrak-Toydemir P. , et al. RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndrome. Am J Med Genet A 2016; 170 (06) 1450-1454
• 23 Grillner P, Söderman M, Holmin S, Rodesch G. A spectrum of intracranial vascular high-flow arteriovenous shunts in RASA1 mutations. Childs Nerv Syst 2016; 32 (04) 709-715
• 24 Thiex R, Mulliken JB, Revencu N. , et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. AJNR Am J Neuroradiol 2010; 31 (04) 775-779
• 25 Amyere M, Revencu N, Helaers R. , et al. Germline loss of function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling. Circulation 2017; pii: CIRCULATIONAHA.116.026886 . [Epub ahead of print]. Available at: www.ncbi.nlm.nih.gov/pubmed/28687708 . Accessed July 20, 2017
• 26 Erkek E, Hizel S, Sanlý C. , et al. Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome. J Am Acad Dermatol 2005; 53 (04) 639-643
• 27 Tan WH, Baris HN, Burrows PE. , et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007; 44 (09) 594-602
• 28 Srinivasa RN, Burrows PE. Dural arteriovenous malformation in a child with Bannayan-Riley-Ruvalcaba Syndrome. AJNR Am J Neuroradiol 2006; 27 (09) 1927-1929
• 29 Kurek KC, Howard E, Tennant LB. , et al. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol 2012; 36 (05) 671-687
• 30 Ngeow J, Sesock K, Eng C. Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat 2017; 165 (01) 1-8 . doi: 10.1007/s10549-015-3665-z.
• 31 Ngeow J, Eng C. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol. Methods 2015; 77-78: 11-19
• 32 Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet 2013; 163C [phone]
• 33 Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18 (02) 400-407